Regulatory document
EMEA public statement on Refacto (moroctocog alfa): Introduction of a change to Refacto…
EMA · Information · EU · May 27, 2003
Key facts
| Title | EMEA public statement on Refacto (moroctocog alfa): Introduction of a change to Refacto drug product specific activity specification increase of 20% in the amount of Refacto protein in each vial |
|---|---|
| Issuer | European Medicines Agency |
| Source | EMA |
| Document type | Information |
| Country or region | EU |
| Date | May 27, 2003 |
| Document | ema.europa.eu |
| Issuer website | ema.europa.eu |
At a glance
- Yes Full text searchable in Orca1
- 1,000+ Documents from this issuer in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Global regulations and guidance
Regulations, guidance and official notices from medical device and medicines regulators worldwide, collected by Orca1 from each issuer's website. Only the title, issuer, date and link are shown here; the full text is searchable in Orca1.
Source: Medical device and medicines regulators and agencies as named on each record (EMA, MHRA, TGA, CDSCO, PMDA, NMPA, Health Canada, HSA, the FDA and others), collected by Orca1 from each issuer's website · Source date: